Intralesional treatment with meglumine antimoniate in three patients with New World cutaneous leishmaniasis and large periarticular lesions with comorbidities
Rev. Soc. Bras. Med. Trop
;
50(2): 269-272, Mar.-Apr. 2017. tab, graf
Article
Dans Anglais
| LILACS
| ID: biblio-842839
ABSTRACT
Abstract Although New World cutaneous leishmaniasis is not itself a life-threatening disease, its treatment with systemic antimonials can cause toxicity that can be dangerous to some patients. Intralesional meglumine antimoniate provides a viable, less toxic alternative. Herein, we describe an alternative treatment with subcutaneous intralesional injections of meglumine antimoniate into large periarticular lesions of three patients with cutaneous leishmaniasis and comorbidities. This treatment was safe, successful, and well tolerated. This case series suggests that intralesional meglumine antimoniate is an effective therapy for cutaneous leishmaniasis, even with periarticular lesions. This hypothesis should be tested in controlled clinical trials.
Texte intégral:
Disponible
Indice:
LILAS (Amériques)
Sujet Principal:
Composés organométalliques
/
Leishmaniose cutanée
/
Méglumine
/
Antiprotozoaires
Limites du sujet:
Adulte très âgé
/
Femelle
/
Humains
/
Mâle
langue:
Anglais
Texte intégral:
Rev. Soc. Bras. Med. Trop
Thème du journal:
Médecine tropicale
Année:
2017
Type:
Article
Pays d'affiliation:
Brésil
Institution/Pays d'affiliation:
Fundação Oswaldo Cruz/BR
Documents relatifs à ce sujet
MEDLINE
...
LILACS
LIS